Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

French pharmaceutical company Sanofi confirmed on Monday its plans to sell a controlling stake in its consumer health unit Opella to a US investment fund, after providing the French government ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma last week, J&J has wasted little time hitting back with new data on its ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

Regeneron REGN-0.84%decrease; red down pointing triangle Pharmaceuticals and Sanofi SAN 0.18%increase; green up pointing triangle have won U.S. Food and Drug Administration expanded approval of ...

Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as it considers whether to seek a sale or listing of the business. The ...

(Bloomberg) -- Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential liabilities related to a brand that sold talcum powder ...

PARIS, Oct 11 (Reuters) - Sanofi (SASY.PA), opens new tab has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier ...

In October 2023, Sanofi SA (NASDAQ:SNY) announced its plans to spin off its consumer healthcare business as the French pharmaceutical company outlined its strategic update to increase investment ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bank of America Securities analyst Graham Parry maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €122.00. Graham Parry has given his Buy rating due ...